| Market Cap | ₹290.06 CrCap size |
|---|---|
| Revenue TTM | ₹183.25 CrOperating |
| RSI | 78.66Overbought |
| 1Yr Price Change | 79.13%Stock Performance |
| Execution period | 5 years |
Key highlights
- Exclusive five-year distribution agreement starting January 1, 2027
- HEINE's 2026 Indian market revenue contribution estimated at Rs. 30 crore
- Targeted partnership turnover increase to Rs. 70 crore by the year 2031
- Agreement covers diagnostic tools for ENT, ophthalmology, and dermatology
- Supports QMS's corporate target of reaching Rs. 500 crore revenue by FY29
Strategic Exclusive Partnership
QMS Medical Allied Services has entered into a definitive agreement with German-based HEINE Optotechnik, a global leader in primary diagnostic instruments. Under this contract, QMS will serve as the sole distributor for HEINE across India for a period of five years, beginning January 1, 2027. The agreement prevents HEINE from appointing any other distributor, dealer, or commercial partner in the region.
This collaboration covers a comprehensive product range, including instruments for general medicine, ENT, dermatology, and veterinary diagnostics, alongside power sources and digital documentation systems. The deal was formalized at HEINE's headquarters in Gilching, Germany.
Revenue Projections and Growth Impact
The partnership is poised to act as a significant growth catalyst for QMS's product vertical. HEINE’s net revenues from the Indian market for calendar year 2026 are anticipated to be approximately 2.6 million Euros, equivalent to roughly Rs. 30 crore.
Through its pan-India distribution network, QMS expects to scale this turnover to Rs. 70 crore by 2031. This expansion is a key component of the company's objective to surpass the Rs.
500 crore revenue milestone by FY29. The collaboration allows QMS to leverage its existing relationships with over 50 pharmaceutical companies and a patient reach exceeding 10 lakh individuals.
Management Vision
The exclusive partnership is central to our product business expansion strategy and will help us accelerate our growth trajectory over the next five years. Besides, this collaboration will open more doors for the company to capitalise on its wider presence and established reputation in a fast-growing Indian healthcare space.
Business Overview and Market Context
- QMS is an integrated healthcare provider recently migrated to the NSE mainboard in June 2026.
- The company operates across medical products and services including patient screening and disease management.
- HEINE Optotechnik, founded in 1946, is represented in over 120 countries with a workforce of 500 employees.
- Current financial metrics show a Price to Earnings (PE) TTM of 24.34 against an industry average of 27.18.
- The company maintains a promoter holding of 68.11% as of the latest reporting period.
| Share price | ₹150 |
|---|---|
| Market capitalisation | ₹290.06 Cr |
| Revenue (annual) | ₹172.88 Cr |
| Net profit (annual) | ₹11.92 Cr |
| Revenue (latest quarter) | ₹56.87 Cr+28.01% vs previous quarter |
| Net profit (latest quarter) | ₹3.65 Cr+160.34% vs previous quarter |
| P/E (TTM) | 24.34×Sector 58.92× |
| Promoter holding | 68.11%0.00% QoQ |
| FII holding | 0%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by QMS Medical Allied Services Limited announcing an exclusive five-year agreement with HEINE Optotechnik. Market figures from a third-party data provider.
